Related content

Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor B

By Gilbert Rodney   Fowler Darren   Angus Elizabeth   Hardy Stephen   Stanley Louise   Goodship Timothy  

Pediatric Nephrology, Vol. 28, Iss. 8, 2013-08 ,pp. : 1315-1318

Springer Publishing Company

Access to resources Recommend Favorite

Food and Drug Administration (FDA) Postmarket Reported Side Effects and Adverse Events Associated with Pulmonary Hypertension Therapy in Pediatric Patients

By Maxey Dawn   Ivy D.   Ogawa Michelle   Feinstein Jeffrey  

Pediatric Cardiology, Vol. 34, Iss. 7, 2013-10 ,pp. : 1628-1636

Springer Publishing Company

Access to resources Recommend Favorite

Successful treatment of DEAP-HUS with eculizumab

By Noone Damien   Waters Aoife   Pluthero Fred   Geary Denis   Kirschfink Michael   Zipfel Peter   Licht Christoph  

Pediatric Nephrology, Vol. 29, Iss. 5, 2014-05 ,pp. : 841-851

Springer Publishing Company

Access to resources Recommend Favorite

Antibodies to intimin and secreted proteins A and B in patients with enterohemorrhagic infections

By Karpman D.   Békássy Zivile D.   Sjögren Ann-Christine   Dubois Maria S.   Karmali Mohamed A.   Mascarenhas Mariola   Jarvis Karen G.   Gansheroff Lisa J.   O’Brien Alison D.   Arbus Gerald S.   Kaper James B.  

Pediatric Nephrology, Vol. 17, Iss. 3, 2002-03 ,pp. : 201-211

Springer Publishing Company

Access to resources Recommend Favorite

Treatment of DEAP-HUS—seeking the best strategy

By Licht Christoph   Noone Damien  

Pediatric Nephrology, Vol. 29, Iss. 5, 2014-05 ,pp. : 941-942

Springer Publishing Company

Access to resources Recommend Favorite